I ventured into investing in high school in 2011, mainly in REITs, preferred stocks, and high-yield bonds, starting a fascination with markets and the economy that has not faded despite the years. More recently I have been combining long stock positions with covered calls and cash secured puts. I approach investing purely from a fundamental long-term point of view. On Seeking Alpha I mostly cover REITs and financials, with occasional articles on ETFs and other stocks driven by a macro trade idea.Analyst’s D ...

China's dominance in mineral processing — not mining — is emerging as the defining fault line in the global race for critical resources such as copper. The U.S. imports roughly 60% of the copper it consumes — a reliance drawing fresh scrutiny as demand accelerates across electrification, AI infrastructure, and defense.Track copper price via CPER ETF here.In an exclusive email interview with Benzinga, John Shively, CEO of Pebble Mine, Alaska (the largest untapped copper mine in the U.S.) framed the issue as ...

Core Insights - Institutional investors are experiencing significant outflows from crypto investment products, with nearly $990 million withdrawn in the third week of December, primarily from the United States [1][7] - The ongoing delays in the U.S. Congress regarding the Digital Asset Market Clarity Act (CLARITY Act) are contributing to investor hesitance and regulatory uncertainty [2][3] Group 1: Market Trends - Ethereum-based investment products faced the largest outflows, losing approximately $555 million, while Bitcoin products saw $460 million in net outflows [3][7] - Despite the withdrawals, total crypto inflows for 2025 are significantly higher than in 2024, with year-to-date inflows at around $12.7 billion compared to $5.3 billion [4] Group 2: Selective Investment Behavior - Some altcoins, such as Solana and XRP, showed resilience with net inflows of $48.5 million and $62.9 million respectively, indicating a selective investment approach among investors [5][6] - The interest in specific assets suggests a portfolio rotation rather than a complete exit from the crypto sector [6] Group 3: Regulatory Context - The CLARITY Act aims to clarify the regulatory framework for digital assets in the U.S., defining the roles of the SEC and CFTC, which is crucial for reducing uncertainty in the market [8]

Regulatory Update - SEC closes four-year investigation into Aave Protocol without recommending enforcement action [1] - The decision ends nearly four years of regulatory uncertainty around Aave [1]

Core Insights - Regeneron Pharmaceuticals, Inc. (REGN) is a major player in the biotechnology industry, with a market cap of $82.5 billion and a portfolio of nine marketed drugs [1][2] Company Overview - REGN is classified as a large-cap stock, reflecting its significant size and influence in the biotechnology sector [2] - The company has a strong product lineup, including key products like Eylea and Dupixent, which contribute to its financial success [2] Stock Performance - REGN's stock has experienced a 33.5% increase over the past three months, outperforming the S&P 500 Index, which gained 5.4% in the same period [3] - Year-to-date, REGN shares have risen 10.2%, while over the past 52 weeks, they have climbed 4.2%, underperforming the S&P 500's YTD gains of 15.8% and 13.1% over the last year [4] Recent Developments - On October 28, REGN shares surged 11.8% following the release of Q3 results, with an adjusted EPS of $11.83 surpassing Wall Street's expectations of $9.44 [5] - The company's revenue for the quarter was reported at $3.8 billion, exceeding the forecast of $3.6 billion [5] Competitive Landscape - Incyte Corporation (INCY) has shown stronger performance compared to REGN, with a 53% gain year-to-date and a 41.2% increase over the past 52 weeks [6] Challenges - REGN faces challenges such as increased scrutiny on drug pricing, regulatory uncertainties, and competition from larger pharmaceutical companies, which may impact its growth prospects [5]

Core Viewpoint - Regeneron Pharmaceuticals, Inc. has faced underperformance in its stock compared to broader market indices and biotechnology ETFs, despite a recent positive earnings report that exceeded expectations [2][3][4]. Company Overview - Regeneron Pharmaceuticals, based in Tarrytown, New York, is valued at $73.9 billion and has a portfolio of nine marketed drugs, including Eylea and Dupixent [1]. Stock Performance - Over the past year, Regeneron's stock has declined marginally, while the S&P 500 Index has increased by nearly 10.5% [2]. - Year-to-date, Regeneron stock is up 3.5%, compared to an 11.2% rise in the S&P 500 [2]. - The iShares Biotechnology ETF has outperformed Regeneron, gaining about 21.8% over the past year and 24.2% year-to-date [3]. Earnings Report - On October 28, Regeneron shares rose by 11.8% following the Q3 earnings report, which showed an adjusted EPS of $11.83, surpassing Wall Street's expectation of $9.44 [4]. - The company's revenue for the quarter was $3.8 billion, exceeding the forecast of $3.6 billion [4]. Analyst Expectations - For the current fiscal year ending in December, analysts project a 9.8% decline in EPS to $34.84 on a diluted basis [5]. - Regeneron has a mixed earnings surprise history, beating estimates in three of the last four quarters [5]. - Among 28 analysts covering Regeneron, the consensus rating is a "Moderate Buy," with 18 "Strong Buy" ratings, two "Moderate Buys," seven "Holds," and one "Moderate Sell" [5]. Price Targets - William Pickering from Bernstein recently assigned a "Buy" rating with a price target of $818, indicating an 11% potential upside [6]. - The mean price target is $755.22, representing a 2.5% premium to current levels, while the highest target of $910 suggests a 23.5% upside potential [6].

Group 1 - The article does not provide any specific content related to a company or industry [1]

Core Viewpoint - The Trump administration's decision to halt fully permitted offshore wind energy projects is seen as "very damaging" to investment in the energy sector, according to Shell US President Colette Hirstius [1][4]. Group 1: Impact on Offshore Wind Projects - The cancellation of $679 million in federal funding for 12 offshore wind projects by the Trump administration is a significant setback for the industry, which was a key focus of former President Joe Biden's climate and energy agendas [5]. - Hirstius emphasized that energy projects with proper permits should be allowed to continue, indicating a need for stability in the regulatory environment [2][4]. Group 2: Regulatory Environment and Future Outlook - Hirstius warned that the political pendulum in the US could swing back against the oil and gas sector, highlighting the uncertainty in the regulatory environment as a major concern for investment [2][4]. - The potential for regulatory changes could impact the development of energy projects, with Hirstius expressing a desire to see previously permitted projects continue to be developed [4].

Core Insights - Global trade has become increasingly uncertain, with tariffs now a permanent aspect of the economic landscape for U.S. businesses [1][6] - Mid-market companies are focusing on maintaining profitability while managing customer relationships amidst rising costs [2][4] Impact of Tariffs - 90% of goods firms and over 70% of services firms have raised prices due to tariffs and macroeconomic pressures, yet 75% of goods executives and nearly 50% of services firms report shrinking profit margins [3] - Approximately 75% of goods and services companies have experienced weakening demand, indicating that higher prices may not sustain sales volumes and could harm brand loyalty [4] Strategic Adjustments - Many firms are opting for structural changes rather than solely relying on price increases, with nearly all mid-market firms implementing strategies beyond price hikes [5] - Key strategies include product discontinuations, redesigns, and supplier negotiations to manage costs without further burdening consumers [9] Long-Term Perspective on Tariffs - Nearly half of product leaders view tariffs as a permanent fixture in U.S. trade policy, prompting firms to invest in redesign and supply chain restructuring [6][7] - Executives with a positive business outlook are more likely to treat tariffs as a long-term issue, facilitating proactive planning [7] Regulatory Uncertainty - Over 70% of executives report moderate regulatory uncertainty, which has increased from the previous year, adding complexity to operational decisions [10] - The combination of tariffs and regulatory changes has led firms to delay investments and increase compliance spending, necessitating structural adaptations to maintain margins [11]

Market Overview - Stablecoins are experiencing rapid growth but represent approximately 1% of the global money supply [1] Challenges & Obstacles - Regulatory uncertainty is hindering wider adoption [1] - Clunky user experience (UX) poses a barrier [1] - Weak incentives and infrastructure gaps exist [1] Adoption Hurdles - Interoperability issues, such as chain compatibility, impede seamless USDC transfers [1] - ZeroHashX Chief Business Officer suggests that adoption will be limited if users need to understand the underlying blockchain technology for transactions [1]